Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood pressure drug response varies by ethnicity, study finds

NCT ID NCT02847338

Knowledge-focused Sponsor: Cambridge University Hospitals NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested how well different blood pressure drugs work in White, Black, and South Asian people. About 940 adults with high blood pressure took one or two common medicines. The goal was to see if response differs by ethnicity, which could help doctors personalize treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
amlodipine, lisinopril, amiloride, chlortalidone
What this could lead to
If successful, this could help doctors choose the most effective blood pressure medication based on a person's ethnic background, leading to better control and fewer side effects.
What could go wrong
This is a completed Phase 4 study, so results are available, but it only looked at specific ethnic groups and may not apply to everyone. The findings may not change current treatment guidelines immediately.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

940 people

The number who actually took part.

Start date

Nov 2016

Finished

Oct 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: To be included in the trial the participant must: 1. Have given written informed consent to participate 2. Be aged 18 to 65 years inclusive 3. Self-Define Ethnicity: participants should SELF IDENTIFY into 1 of the three groups below: White White British White Irish Any other white background Black or Black British Black Caribbean Black African Any other black background Asian or Asian British Asian Indian Asian Pakistani Asian Bangladeshi Any other Asian background 4. Be hypertensive defined as:- Mono-therapy rotation 1. currently untreated with EITHER an ABPM day time average blood pressure ≥ 135mmHG (systolic) or ≥ 85mmHg (diastolic) OR Home BP measurements using a validated device based on the average of 10 blood pressure readings of ≥135 mmHg (systolic) or ≥85 mmHg (diastolic) 2. Patients who may be taking antihypertensive drugs at sub therapeutic doses or in ineffective combinations, and who are felt likely to be controllable on a study drug and willing and able to be washed out, at the discretion of the CI (Chief Investigator) / PI (Principal Investigator), can enter the trial if they meet the above criteria. Dual therapy rotation a.Treated hypertensive receiving one to three antihypertensive drugs with a blood pressure (ABPM daytime average blood pressure or Home BP as in a.) between 135 or 200 mmHg (systolic) AND between 85 or 110 mmHg (diastolic). Exclusion Criteria: The presence of any of the following will mean participants are ineligible: * Participant does not fit into one of the defined ethnic groups e.g. Mixed * Pregnant or breastfeeding women * Known or suspected secondary hypertension * Significant sensitivity or contraindications to any of the study medications * Participants taking lithium or are regularly consuming non-steroidal anti-inflammatory drugs at variable doses * Requirement to take any of the study drugs continuously e.g. ACEi and heart failure * Any clinically significant hepatic impairment * Any clinically significant kidney impairment * Concurrent participation in another clinical trial using systemic vasoactive medications or medications known to interact with the study drugs (participation in another study as part of the AIM HY mechanistic or social science programme will not be an exclusion criterion) * Patients who are deemed unsuitable by the investigator on clinical grounds

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertension

Contacts and locations

Locations

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom

  • Hammersmith & Fulham GP Partnership: Richford Gate Medical Practice

    London, W6 7HL, United Kingdom

  • Heartlands Hospital

    Birmingham, B9 5SS, United Kingdom

  • Lister Hospital

    Stevenage, SG1 4AB, United Kingdom

  • Liverpool Heart and Chest Hospital

    Liverpool, L14 3PE, United Kingdom

  • Manchester Royal Infirmary

    Manchester, M13 9WL, United Kingdom

  • Nottingham University Hospital: QMC Campus

    Nottingham, NG7 2UH, United Kingdom

  • Queen Elizabeth Hospital

    Birmingham, B15 2TH, United Kingdom

  • Sandwell & West Birmingham Hospitals NHS Trust

    Birmingham, B18 7QH, United Kingdom

  • St George's Hospital

    London, SW17 0RE, United Kingdom

  • St Thomas' Hospital

    London, SE1 7EH, United Kingdom

  • University Hospital Llandough

    Cardiff, CF64 2XX, United Kingdom

  • University of Glasgow

    Glasgow, G12 8TA, United Kingdom

  • William Harvey Research Institute, Barts and the London Medical School

    London, EC1M 6BQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.